In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
Search results for: hospital
Wisconsin Rheumatology Association Targets Rural Workforce Shortages, Advocacy Needs
Now in its 16th year, the Wisconsin Rheumatology Association engages and supports rheumatology professionals through advocacy sessions, annual meetings and continuing medical education-accredited events.
Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease
COVID-19-related deaths are significantly higher in communities with higher proportions of Black, Latinx, Asian American or other racial/ethnic minorities.
What Happens When Patients Have Access to Their Clinician’s Notes?
Navigating the healthcare system and its processes can seem overwhelming to patients. If patients understand why their clinician recommended something, know how and when to take medications, and why they shouldn’t skip a dose—or 10—they may not feel so out of control. Sharing examination notes with patients can be helpful to many patients who struggle…
Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis
Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.
Immunosuppressive Medicines Do Not Worsen COVID-19 Outcomes
(Reuters)—Medications that suppress the immune system—necessary for many chronic diseases—do not worsen outcomes of COVID-19 cases, new data suggest. Researchers looked back at 2,121 adults hospitalized for COVID-19 between March and August, including 108 who were taking immunosuppressive drugs (primarily prednisone, tacrolimus or mycophenolate mofetil). After accounting for patients’ general baseline health status, researchers found…
The Effects of IL-17A Inhibitors on the Microbiota
The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…
Rheum After 5: Dr. Angus Worthing, the Singing Rheumatologist
Every Christmas Eve, Angus Worthing, MD, FACP, FACR, his wife, Margaret, and two young children, engage in a sing-off over the phone, competing against a professional quartet comprising his best friend, Doug, Doug’s sister and their parents. Dr. Worthing, a partner at Arthritis & Rheumatism Associates in Washington, D.C., demonstrated his musical talent as a…
The ACR’s 2020 Advocacy Year in Review
To say it has been an interesting (the science and the memes), tumultuous (the politics) and heartbreaking (the pandemic and social injustice) year is an understatement. There have been moments of grace and inspiration that we hope have kept everyone going. As we look to 2021, we take lessons from our experiences in 2020. Washington,…
Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap
Drug-induced lupus erythematosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 323
- Next Page »